CCS is a growing clinical burden worldwide, particularly in the Gulf region.

Current guideline recommendations for anti-anginal escalation have a limited evidence base.

Nitrates are frequently used for the treatment of CCS but have their limitations.

Nicorandil is a useful therapeutic option offering vasodilatory and cardioprotective effects.

Nicorandil has a contemporary randomised evidence base and a favourable clinical profile.